ORIC Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
ORIC Pharmaceuticals, Inc. filed this Form 8-K on August 11, 2022, reporting the issuance of a press release containing financial results for the fiscal quarter ended June 30, 2022. The company is a Delaware corporation listed on Nasdaq under the symbol ORIC.
Financial Results and Key Metrics
The filing references the quarterly financial results press release as Exhibit 99.1, but the provided filing text does not include the press release’s financial data. Revenue, net loss, cash flow, margins, debt, liquidity, cash balance, and other key financial metrics cannot be determined from the available text.
Material Changes Versus the Prior Comparable Period
The filing text does not provide comparative financial results or a clear description of material changes from the prior-year or prior-quarter period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risk discussion, contingencies, or unusual items are included in the provided text. The filing solely furnishes the referenced earnings press release and related exhibit information.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for the complete quarterly financial results.
- Verify reported cash, cash equivalents, investments, operating cash burn, and estimated liquidity runway.
- Verify research and development expenses, general and administrative expenses, and net loss compared with the prior comparable period.
- Review any clinical, regulatory, financing, or corporate updates contained in the press release.
- Note that the information furnished under Item 2.02 and Item 9.01 is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.